Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Cardiology Drug Data - A-Z (Espanol)
Drug Class Description
Asociaciones betabloqueante con diureticoDrug Description
COMPRIMIDOSPresentation
- Hipertensión (oral): 1 comprimido/24 h, tomado preferentemente por la mañana.Indications
Hipertensión.Adult Dosage
Sustancia prohibida en el deporte de competición, susceptible de producir un resultado positivo en un control de dopaje.Interactions
Este medicamento puede potenciar la toxicidad de sales de litio, clonidina, ergotamina, nifedipina, prazosina, simpaticomiméticos de acción directa (adrenalina) o verapamilo; puede reducir el efecto de los antidiabéticos (insulina, glibenclamida). La eficacia de este medicamento puede ser reducida por antiácidos, antiinflamatorios no esteroídicos (indometacina, ácido acetilsalicílico), resinas de intercambio iónico (colestiramina) o sulfinpirazona; su toxicidad puede ser potenciada por anestésicos generales (halotano), disopiramida, antidepresivos IMAO (fenelzina) o quinidina.Adverse Reactions
Las reacciones adversas son más frecuentes al inicio del tratamiento y, por lo general, desaparecen después de 1-2 semanas. Los efectos adversos más característicos son: Fatiga, mareos, cefalea, insomnio, depresión, broncoespasmo, vasoconstricción periférica con extremidades frías y con hormigueo, alteraciones metabólicas (hiperglucemia, ataques de gota en pacientes predispuestos, hiponatremia e hipopotasemia), calambres musculares (más frecuente en ancianos). -Con menor frecuencia: alteraciones cardiovasculares (bradicardia, bloqueo auriculoventricular, insuficiencia cardiaca e hipotensión), alucinaciones, somnolencia, confusión, parestesia, neuropatía periférica, miopatía, escozor ocular, visión borrosa e hipoglucemia, náuseas, vómitos, diarrea o estreñimiento, calambres abdominales, erupciones exantemáticas, prurito, alopecia reversible, trombocitopenia, agranulocitosis, púrpura no trombocitopénica, eosinofilia pasajera, impotencia, reducción de la líbido, fibrosis pulmonar y pleuresía. El tratamiento debe ser suspendido inmediatamente en el caso de que el paciente experimente algún episodio de insuficiencia cardiaca o bradicardia excesiva.Manufacturer
FIDES ECOPHARMADrug Availability
APORTACION REDUCIDA (CICERO)Advert for Healthcare Professionals Only
Related News
New review of Cryoballoon Ablation treatment for Atrial Fibrillation Cardiology Page
A new research review comparing the efficacy and safety of cryoballoon ablation for Atrial Fibrillation finds that a single cryoballoon ablation procedure for paroxysmal AF results in high acute and medium-term efficacy rates, with lower success rates when used as stand-alone therapy for persistent AF. The rate of complications is relatively low and includes a 6.38% incidence of PNP, most of which is transient. The review also looks at results of the STOP-AF trial, which found that 70 percent of patients with Atrial Fibrillation who were treated with Medtronic's Arctic Fox cryoballoon ablation freezing technique are free of any heart rhythm irregularities one year out from having the procedure. (Heart Rhythm, Volume 8, Issue 9 , Pages 1444-1451, September 2011)
New Drug Eluting Stents safer for PCI patients Cardiology Page
Results from the SCAAR Study, presented at the European Society of Cardiology Congress 2011, showed that Percutaneous Coronary Intervention with "new generation" Drug Eluting Stents (DES), was associated with a 38% lower risk of clinically meaningful restenosis and a 50% lower risk of stent thrombosis compared to old generation DES. The SCAAR study evaluated the long-term outcome in all patients who underwent stent implantation with bare metal stents, "older generation" drug eluting stents, and "new generation" drug eluting stents in Sweden. Further studies are needed to discriminate which component of the new generation DES is involved in decreasing the incidence of stent thrombosis and restenosis.
EMA confirms risk benefit of Multaq Cardiology Page
EMA has confirmed a positive benefit-risk balance for Multaq (dronedarone) from Sanofi- Aventis for the treatment of a newly defined population of paroxysmal and persistent Atrial Fibrillation patients, following its review under the Article 20 procedure. A new indication for Multaq is: indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation.
